Related Experiment Video
Updated: Sep 9, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Therapeutics update in immune-mediated rheumatic diseases: Rheumatoid arthritis, idiopathic inflammatory myositis and
Caroline Zollinger-Read1, Andrew Filer1
1Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Abstract:
Immune-mediated inflammatory diseases (IMIDs) are a group of common clinically diverse conditions that are characterised by systemic inflammation. They often pose medical challenges due to their multi-organ involvement, chronicity, associated comorbidities and poor impact on quality of life for patients. The management for IMIDs has changed profoundly over the past 20 years, with the paradigm of treatment shifting away from broad immunosuppression towards pathway-specific targeted treatment. This editorial will focus on three immune mediated rheumatic diseases that physicians may encounter in their clinical practice; rheumatoid arthritis (RA), idiopathic inflammatory myositis (IIM) and anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis (AAV). This editorial will provide a concise overview of the current targeted treatment landscape of these three conditions.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pericarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

